Health Care Cost

Experts explain that DTC models could improve medication adherence through convenience and incentives, but higher costs may limit their effectiveness.

As open enrollment continues, 77% of surveyed Americans were happy with their options for 2026 health care coverage, although cost concerns surfaced.

Polarized dermatoscopes produced higher-quality teledermatology images but at greater cost, raising questions about feasibility and equitable access.

Self-pay emergency department prices rose significantly from 2021 to 2023, especially at for-profit and system-affiliated hospitals, highlighting growing affordability challenges for uninsured and underinsured patients.

Jennifer Graff, PharmD, and Brian Reid, MS, emphasize that DTC pharmacy models can give patients more convenient access to medications but may increase out-of-pocket costs.

With ACA subsidies ending in 2025, Ben Light explains how rising premiums may push individuals toward ICHRAs and reshape employer health coverage strategy.

A new study shows fee-for-service care is linked to higher odds of low-value surgery, suggesting salaried models may reduce unnecessary procedures.

The guidelines highlight the need for lifelong obesity management, early diagnosis, comorbidity prevention, and patient-centered care.

This commentary proposes a hybrid drug pricing reform model balancing most favored nation (MFN) benchmarking with domestic negotiation strategies that drive equity-focused valuation frameworks.

New research shows immigrant children face higher odds of unmet medical needs as federal and state coverage rules narrow.

Within the same physician groups, 2-sided risk in Medicare Advantage (MA) was associated with higher quality and lower utilization for dually eligible beneficiaries compared with fee-for-service MA and traditional Medicare.

Shared savings reflects continued growth of long-term-care ACOs in Medicare’s value-based models.

Eleanor Perfetto, PhD, explores how most favored nation policy relates to broader drug pricing and cost-effectiveness debates in the US.

The expansion of direct-to-consumer (DTC) pharmaceutical manufacturer models and the upcoming TrumpRx launch offer lower costs but create new complexities for patients.

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

With ACA subsidies and key CMS payment models ending in 2025, premiums are set to rise, shifting costs to consumers and employers.

Requiring individuals on Medicaid to report their work hours has been attempted in other states previously, with mixed results.

Jasmine Eugene, PharmD, explains how pharmacists practicing at the top of their license improve rural oncology access and ease physician workload.

Clark Alsfeld, MD, discusses how telemedicine, pharmacists, and evolving policies help overcome financial and geographic barriers in oncology care.

Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine.

Cuts to Medicaid could spell trouble for pediatric health, as millions of children rely on Medicaid to cover their hospital expenses.

Broader eligibility, real-world data, and community partnerships are expanding access to CAR T-cell therapy.

Ochsner MD Anderson expands cancer care access in Louisiana through community partnerships, technology, and strong patient-physician relationships.

One in 5 of the highest-revenue drugs of 2022 was exclusively approved for rare conditions, accounting for more than 7% of US pharmaceutical spending.

Experts say proposed pharmaceutical tariffs could raise drug prices, impacting patient access and health care budgets.